CSL Behring – driven by our promise
Products for coagulation therapies, intensive care and immunology therapies
CSL Behring is a global leader in the plasma protein biotherapeutics industry. The company is committed to treating rare, serious diseases and to improving the quality of life of patients all over the world. CSL Behring’s has a tradition of keeping its promises that goes back more than one hundred years. The company produces an extensive range of plasma-based and recombinant therapies and distributes them worldwide.
CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company based in Melbourne, Australia.
Marburg is CSL Behring’s largest research and production site, employing around 2,400 staff.